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Abstract
Introduction
The aim of this study was to assess the utility of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-
exendin-4 scintigraphy in the management of patients with hypoglycemia, particularly in the
detection of occult insulinoma.
Materials and Methods
Forty patients with hypoglycemia and increased/confusing results of serum insulin and C-
peptide concentration and negative/inconclusive results of other imaging examinations
were enrolled in the study. In all patients GLP-1 receptor imaging was performed to localise
potential pancreatic lesions.
Results
Positive results of GLP-1 scintigraphy were observed in 28 patients. In 18 patients postsur-
gical histopathological examination confirmed diagnosis of insulinoma. Two patients had
contraindications to the surgery, one patient did not want to be operated. One patient, who
presented with postprandial hypoglycemia, with positive result of GLP-1 imaging was not
qualified for surgery and is in the observational group. Eight patients were lost for follow up,
among them 6 patients with positive GLP-1 scintigraphy result. One patient with negative
scintigraphy was diagnosed with malignant insulinoma. In two patients with negative scintig-
raphy Munchausen syndrome was diagnosed (patients were taking insulin). Other seven
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patients with negative results of 99mTcGLP-1 scintigraphy and postprandial hypoglycemia
with C-peptide and insulin levels within the limits of normal ranges are in the observational
group. We would like to mention that 99mTc-GLP1-SPECT/CT was also performed in 3 pts
with nesidioblastosis (revealing diffuse tracer uptake in two and a focal lesion in one case)
and in two patients with malignant insulinoma (with the a focal uptake in the localization
of a removed pancreatic headin one case and negative GLP-1 1 scintigraphy in the other
patient).
Conclusions
99mTc-GLP1-SPECT/CT could be helpful examination in the management of patients with
hypoglycemia enabling proper localization of the pancreatic lesion and effective surgical
treatment. This imaging technique may eliminate the need to perform invasive procedures
in case of occult insulinoma.
Introduction
Hypoglycemia is a decreased blood glucose concentration (less than 70 mg/dl (3.9 mmol/l))
and is connected usually with specific symptoms such as tremor, anxiety, sweating, irritability,
impaired vision, weakness and fatigue. Prolonged or recurrent severe hypoglycemia may lead
to impaired brain function and even death [1–3]. Except for diabetic patients hypoglycemia is
not a common problem. However searching for the cause of hypoglycemia and then therapy of
diagnosed underlying disease is often difficult.
If there was no previous evidence of either taking drug affecting insulin secretion or any crit-
ical illnesses (i.e. hepatic, renal or cardiac failure or severe infection), the management of such
patients is still challenging for clinicians as hypoglycemia might be caused by many reasons.
Endogenous hyperinsulinemia could be related to insulinoma—the occurrence of neoplasm
foci deriving from the pancreatic cells secreting insulin [1]. Severe non-insulinoma hyperinsu-
linemic hypoglycemia could be also associated with other β-cell disorders (e.g. non-insulinoma
pancreatogenous hypoglycemia, post gastric bypass hypoglycemia) [4,5]. Nesidioblastosis
(islet cell hyperplasia) is typically characterized by islet hyperplasia, β-cell hypertrophy, and
increased β-cell mass. There are two forms of nesidioblastosis: a focal form and a diffuse form;
and many cases have a defined genetic basis [6]. While management of patients with insuli-
noma and nesidioblastosis is different this is important to make a proper diagnosis.
Insulinoma is the most common functioning neuroendocrine tumor of the pancreas [7–9].
The laboratory tests used in case of suspicion of insulinoma are 72 hours fasting test with mea-
surement of serum glucose, insulin and C-peptide concentrations [7–9]. Insulinoma are usually
small lesions. Despite the increasing efficacy of standard imaging examinations (computed
tomography (CT) or magnetic resonance imaging (MRI)) in localization of insulinoma, there
are still patients for whom results of all available techniques (including also invasive methods
such as endoscopic ultrasound (EUS) or selective arterial calcium stimulation test) are negative
[7–11]. The experience with the use of labeled somatostatin analogues for imaging of neuroen-
docrine neoplasms shows the utility of nuclear medicine methods in preoperative localization
of the occult tumors. However somatostatin receptor scintigraphy is positive only in about 50–
60% of benign insulinomas [12]. Therefore there is a need to develop a non-invasive diagnostic
procedure, which will improve the managmenet of patients with occult insulinoma.
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Radiolabelled peptides are useful for specific targeting of various neoplasms and are cur-
rently being intensively investigated as a promising strategy in oncology and endocrinology
[12–15]. Glucagon-like peptide-1 (GLP-1) is a short-lived hormone produced by a specific
proteolytic processing of the preproglucagon molecule in intestinal L cells. The main rout
of its action is binding to a specific receptor on the surface of pancreatic islet β-cells stimulat-
ing glucose-induced insulin secretion [16]. This receptor belongs to the G-protein-coupled
receptors subfamily and has been examined to be in a large quantity overexpressed in benign
insulinomas [17]. To the best knowledge of authors, the first studies with iodinated GLP-1
and its antagonist exendin-(9–39) devoted to GLP-1 receptor internalization were performed
in the early nineties [18]. Metabolically more stable constituents of GLP-1, most of all GLP-1
receptor agonists—exendin-3 and exendin-4, have been studied not only in mouse models
but also in humans. [Lys40(Ahx-DTPA)-NH2]-exendin-4 labelled with indium-111 was the
first compound based on a GLP-1 analogue developed and checked in clinical conditions.
111In coupled to exendin-4 via DOTA complexation was examined in individuals. Both
radiopharmaceuticals were able to localise human benign insulinomas which were not
detected by other diagnostic methods. In addition, the GLP-1 receptor imaging gave favour-
able results with a complete recovery of patients after the surgical tumour excision [19–21] in
a long run. The exact preoperative localization of the insulinoma limited surgical interven-
tion only to a precise place in the pancreas and allowed sparing healthy pancreatic tissue.
Patients could return to normal life without necessity of taking medication in the form of
insulin substitutes. Wild and co-workers showed however that GLP-1 scintigraphy has lim-
ited potential in case of malignant insulinoma, which overexpressed mainly somatostatin
receptors [22], in contrast with its benign form. However, the successful localization of
GLP-1 receptor-positive lesions in the liver and a lymph node in patients with malignant
form of insulinoma by [68Ga]Ga-DO3A-VS-Cys40-exendin-4 for PET imaging was also
reported [23].
GLP-1 receptor imaging with 99mTc-labeled exendin-4 provides an alternative strategy to
those labeled with 111In and 68Ga. Owing to the physical properties of isotope and the signifi-
cantly lower tumour and organ uptake of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-
4 in comparison with [Lys40(Ahx-DOTA-111In)NH2]-exendin-4, the estimated effective dose
of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 was calculated and evaluated to be
over 40 times less than the one of its 111In-labeled congener compound. Despite lower
tumor uptake connected to the significantly less efficient internalisation, scintigraphy with
[Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 was also able to detect lesions in the
pancreas with high sensitivity in vivo in an animal model [24]. In 2013 our group have pre-
sented promising results of our pilot study with the use of the new compound ([Lys40(Ahx-
HYNIC-99mTc/EDDA)NH2]-exendin-4) [25]. It was concluded that the GLP-1 receptor
tracer labelled with 99mTc has probably the same high potential to find benign insulinoma
foci, however, in contrast with ones labeled with 111In and 68Ga, it is still cheaper and easier
to obtain, generates lower radiation burden to patients and the staff, and, what is more, it
may be potentially useful for the detection with a γ-probe in an intraoperative localization of
insulinoma [25].
As it was mentioned above initial results of our pilot study (considering eleven patients)
were presented previously in European Journal of Nuclear Medicine and Molecular Imaging
in 2013. Currently we would like to present results of the use of scintigraphy with labeled
GLP-1 analogue in the group of forty patients with hypoglycemia. The aim of this study
was to assess the utility of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 scintigraphy
in the management of patients with hypoglycemia, particularly in the detection of occult
insulinomas.
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Material
Patients
Forty patients (25 women and 15 men; mean age 65.5 ± 12.0 years, min. 16.0 years, max. 87.0
years) with symptoms of hypoglycemia and confirmed serum glucose levels concentrations
below 45 mg/dl (2.5 mmol/l) with increased or confusing results of serum insulin and C-pep-
tide concentrations and negative or inconclcusive results of previously performed imaging
examination (computed tomograpahy—CT, magnetic resonance imaging—MRI, somatostatin
receptor scintigraphy—SRS and endoscopic ultrasonography—EUS), were enrolled in the
study. None of the patients was treated with oral antidiabetic agents. The majority of patients
were selected from patients diagnosed and treated in the Department of Endocrinology of the
University Hospital in Kraków. However there were also patients from four other medical cen-
ters in Poland included in the study.
The study was approved by the local Ethics Committee of Jagiellonian University in Kra-
ków, Poland. All patients provided a written consent in accordance with an accepted documen-
tation, after receiving detailed information about the study procedure.
Method
Imaging technique
Between October 2010 and April 2014 examinations with [Lys40(Ahx-HYNIC-99mTc/EDDA)
NH2]-exendin-4 were performed in Nuclear Medicine Unit Department of Endocrinology
University Hospital in Kraków, Poland in all patients enrolled in the study. The examination
was performed to localize potential insulinoma lesions in the pancreas.
Labelling procedure was developed and lyophilized kits containing [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4 were prepared by Radioisotope Centre POLATOM, National Centre for
Nuclear Research, Otwock, Poland. Preparation of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exen-
din-4 had been described previously [22,23]. The mean activity of [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4 injected intravenously to patients was 740MBq. Initially examinations
were acquired with a dual-head, large field of view E.CAM gamma camera with low-energy high
resolution (LEHR) collimators and images were evaluated with CT examination imposed by soft-
ware fusion. After the installation of the hybrid device Symbia TruePoint T16 (Siemens Health-
care) in the Department all next GLP-1 receptor examinations were acquired on that system. Basic
acquisition protocol for [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 was established on
the one hand to find the optimal acquisition time with the highest tumor to non-tumor ratio
(T/nT ratio) and the lowest kidney to non-tumor ratio (K/nT ratio) at the same time, and on the
other hand to perform dosimetric calculations (described in details by Sowa-Staszczak and co-
workers, [25]). Finally, whole-body and SPECT/CT scans with a low dose CT protocol were per-
formed at two time points, between 3–4 h and 5–6 h after the injection of the GLP-1 analogue
labelled with 99mTc. Volumetric analysis was performed to assess T/nT ratio.
Every patient was carefully checked for any adverse reaction after the injection of the tracer.
Blood pressure and glycemia were monitored at several time points before and after the injec-
tion of the compound in all patients. Some of the patients (including all patients with suspicion
of benign insulinoma) required a glucose infusion at the time of GLP-1 receptor imaging pro-
cedure due to low blood glucose levels (below 40 mg/dl).
The obtained images were assessed by experienced nuclear medicine specialists.
Patients with positive results of GLP-1 receptor imaging were qualified to the surgical exci-
sion of the visualised lesions. The histopathological confirmation of tumor presence and the
evaluation of its type were performed after surgery.
99mTc-GLP1 Scintigraphy in Patients with Occult Insulinoma
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Results
The quality of the obtained [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 images was
evaluated as good. Positive results of GLP-1 scintigraphy were observed in 28 patients
(Table 1). Among them in 18 patients postsurgical histopathological examination confirmed
diagnosis of insulinoma (type G1 neuroendocrine tumours, min. 2 mm, max. 22 mm in size–
Fig 1). The post-surgical resolution of symptoms was observed in all patients.
It is worth to mention, that one of the operated patients (38-year old female) was referred to
the GLP-1 scintigraphy due to severe hypoglycemia after distal pancreatectomy (which was per-
formed because of severe symptoms in spite of negative results of conventional imaging). Based
on focal uptake of labelled GLP-1, patient underwent partial, selective resection of pancreatic
body—histopathological examination revealed coexisting insulinoma and nesidioblastosis.
Three patients were disqualified from surgery. However, the positive results of GLP-1 scin-
tigraphy, clinical and biochemical assessment indicated diagnosis of insulinoma. The first
patient was disqualified from surgery due to severe heart failure (Fig 2). Hypoglycemia was
controlled with diazoxide. The second patient could not have a surgical excision of pancreatic
lesion due to dissemination of kidney cancer. The patient is treated with protein kinase inhibi-
tor. The third patient did not want to be operated.
In case of one patient with positive result of the studied method description of the GLP-1
receptor examination indicated a diffuse uptake of the compound in the whole pancreas with a
small focus of the slightly increased uptake in the body of the pancreas. The patient was not
qualified for a surgery due to confusing results of the laboratory findings (mainly postprandial
hypoglycemia with normal serum insulin and C-peptide concentrations were observed).
Patient is in the observational group.
There was one patient with severe hypoglycemia, increased serum insulin and C-peptide
concentrations and negative result of GLP-1 scintigraphy. The patient was qualified for surgery
(lesion in the head of the pancreas was visualised in CT). The histopathological examination
confirmed NET G2 tumor of the pancreas. However severe hypoglycemia was still observed
after surgery. Finally, based on subsequent imaging studies, a malignant form of insulinoma
was diagnosed (metastases were found in the liver).
Eight patients, among them six with positive GLP-1 scintigraphy results, were lost for follow
up.
In two patients with negative scintigraphy Munchausen syndrome was diagnosed (patients
were taking insulin). Other seven patients with negative results of 99mTcGLP-1 scintigraphy
and postprandial hypoglycemia with C-peptide and insulin levels within the limits of normal
ranges are in the observational group.
We would like to mention that 99mTc-GLP1-SPECT/CT was also performed in three
patients with nesidioblastosis (revealing diffuse tracer uptake in two and a focal lesion in one
case). Two of these patients, who are currently treated with diazoxide, remain under the care of
Department of Endocrinology of University Hospital in Kraków. In the third case, the GLP-1
study revealed a focal uptake of the radiopharmaceutical in the pancreas, what required further
verification. The patient was qualified for a partial pancreatectomy. Unfortunately, the patient
died due to surgery complications. In the analysed histopathological examination, the co-exis-
tence of nesidioblastosis and insulinoma was described.
The examination with labelled GLP-1 was also performed in two patients with malignant
insulinoma. In case of the patient with suspected local recurrence of malignant insulinoma a
focal accumulation of the radiopharmaceutical was revealed in the localization of removed
pancreatic head (to differentiate between the recurrence or metastases to lymph nodes).
There was no uptake observed in liver metastases. The patient did not want to be operated. The
99mTc-GLP1 Scintigraphy in Patients with Occult Insulinoma
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GLP-1 study was negative in the other patient with malignant insulinoma. No serious adverse
reactions were reported by any of the patients at the time of the examination. Due to the natu-
ral disease course of insulinoma it was difficult to observe the relation between the injection of
the tracer and exacerbation of hypoglycemia. Therefore, in order to assess the undisturbed
Table 1. Information about patients and examinations performed.
No Initials Sex Age CT/MR GLP-1 Surgery Final Diagnosis
1 J.A. F 57 - + 1 Insulinoma
2 J.W. M 16 +/- + 1 Insulinoma
3 A.P. M 75 - + 0 Insulinoma (not operated due to severe heart failure)
4 M.K. F 62 - + 1 Insulinoma
5 P.W. M 21 +/- + 1 Insulinoma
6 L.B. M 60 - + 0 Insulinoma (not operated—pt did not agree)
7 S.M. M 52 +/- + 0 Insulinoma (not operated; dissemination of kidney cancer)
8 Z.R. M 58 - + 1 Insulinoma
9 A.Z. F 44 +/- + 1 Insulinoma
10 A.L. F 39 +/- + 1 Insulinoma
11 E.K. F 35 - + 1 Insulinoma
12 E.B. F 19 - + 1 Insulinoma
13 A.B. F 31 +/- + 1 Insulinoma
14 K.B. M 77 +/- + 1 Insulinoma
15 J.A.S. M 38 - + 1 Insulinoma
16 K.J.R. F 40 +/- + 1 Insulinoma
17 K.Ł F 70 - + 1 Insulinoma
18 Z.M. M 56 - + 1 Insulinoma
19 K.C. F 16 +/- + 1 Insulinoma
20 J.S. M 57 - + 1 Insulinoma
21 B.J. F 38 - + 1 Insulinoma
22 B.O. F 40 - - 0 Munchausen syndrome
23 P.D. M 26 - - 0 Munchausen syndrome
24 R.G. M 54 - + ? Lost for follow-up
25 B.G. F 53 - - ? Lost for follow-up
26 K.S. F 50 - + ? Lost for follow-up
27 T.C. M 40 +/- - ? Lost for follow-up
28 K.F. F 50 - + ? Lost for folow-up
29 L.M. F 60 - + ? Lost for follow-up
30 J.B. F 64 +/- + ? Lost for follow-up
31 G.K. F 41 - + ? Lost for follow-up
32 J.K. M 63 - + 0 Not operated; Observation
33 K.T. F 67 +/- - 1 Operated; malignant insulinoma
34 H.K. F 47 - - 0 Observation
35 J.K. F 73 - - 0 Observation
36 K.A. F 34 - - 0 Observation
37 A.A. F 31 - - 0 Observation
38 E.C. F 69 - - 0 Observation
39 P.P. M 19 - - 0 Observation
40 R.P. F 74 - - 0 Observation
F female; M male; + positive result; +/- inconclusive result; CT computed tomography; MRI magnetic resonance imaging; GLP-1 scintigraphy with labeled
GLP-1 analogue; 0 not operated; 1 operated;? no information
doi:10.1371/journal.pone.0160714.t001
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impact of GLP-1 analogues on patients’ blood glucose levels, it was decided to make measure-
ments in the group of patients with medullary thyroid carcinoma (MTC), also diagnosed by
[Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4. Fig 3 presents dependence between the
blood glucose level and time after injection of Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exen-
din-4 in the case of these patients in whom an abnormally diminished blood glucose concen-
tration had not been observed before the examination with labelled GLP-1. The difference
between the blood glucose level before the injection of Lys40(Ahx-HYNIC-99mTc/EDDA)
NH2]-exendin-4 and next measured values did not exceed 10% in general.
Discussion
Preoperative localization of the insulin secreting pancreatic tumors is important for further
effective surgical excision, which should be limited to the affected part of the pancreas. For the
evaluation of neuroendocrine pancreatic tumors in case of computed tomography (CT) and
Fig 1. A 77-year old female—99mTc-GLP1-SPECT/CT. 99mTc-GLP1-SPECT/CT (Single Photo Emission
Computed Tomography/Computed Tomography) revealed bifocal insulinoma (one focus is well visible on the
border of the pancreatic body and tail, T/nT (Target/non-target) ratio 3.4; the second one is smaller, less
visible in the pancreatic tail, T/nT ratio 1.7). Lesions were not detected by other diagnostic methods.
Histopathology confirmed two foci of insulinoma: 9 mm and 2 mm in diameter. A. GLP-1 receptor imaging—
MIP (Maximum Intensity Projection), B. Fusion of GLP-1 receptor imaging and CT—axial slice, C. CT—axial
slice.
doi:10.1371/journal.pone.0160714.g001
Fig 2. A 75-years old male with suspicion of insulinoma—99mTc-GLP1scintigraphy. 99mTc-
GLP1scintigraphy revealed the focus of insulinoma in the pancreas—patient was disqualified from surgical
excision of the tumor due to severe heart failure. The study was performed with dual-head, large field of view
E.CAM gamma camera with low-energy high resolution (LEHR) collimators and images were evaluated with
CT examination imposed by software fusion. A. Fusion of GLP-1 receptor imaging and CT—axial slice, B. CT
—axial slice.
doi:10.1371/journal.pone.0160714.g002
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magnetic resonance imaging (MRI) multiphase, post-contrast series should be used [26]. CT is
more available to patients, but MRI seems to have superior sensitivity and specificity [26].
However, due to small size of the insulinoma tumors, standard imaging procedures such as
ultrasound examination, computed tomography or magnetic resonance imaging are not always
effective in the detection of tumors. For such patients with hyperinsulinemic hypoglycemia
invasive techniques, such as endoscopic ultrasound (EUS) and selective arterial calcium stimu-
lation test (SACST), may be offered [10,11]. However, these are invasive methods and they are
also not always efficient in the detection of occult insulinoma [10,11].
In our paper we present results of the clinical trial with [Lys40(Ahx-HYNIC-99mTc/EDDA)
NH2]-exendin-4 in the detection of benign insulinoma. While the detection of insulinoma (sin-
gle or rarely multifocal forms) in some cases still remains a clinical challenge for four years
[Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 (technetium-99m labelled long acting glu-
cagon-like peptide analogue; 99mTc-GLP) scintigraphy has been developed in our centre as a
potential and crucial imaging technique in such cases.
As surgical excision is the only effective treatment for insulinoma patients, there is a neces-
sity of developing alternative diagnostic strategies for cases with inconclusive results of all
available imaging techniques, possibly through the use of new biomarkers. In 2008, Wild et al.
[19] published the groundbreaking letter which describes the detection of two occult insulino-
mas using indium labelled GLP-1 analogue. Then, it was followed by successful surgery and
the full recovery of the patients. In our study technetium-99m labelled GLP-1 scintigraphy
proved to be also significantly helpful for patients with similar clinical situation.
In presented study GLP-1 receptor imaging with the use of Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4 was positive in case of 28 patients with hypoglycemia. We would like
to emphasize that in case of 18 patients in this group results of standard imaging procedures
(CT and/or MRI) were negative and in the other 10 patients results of CT and/or MRI were
inconclusive. In case of 18 patients postsurgical histopathological examination confirmed diag-
nosis of insulinoma. Three patients with positive results of the GLP-1 receptor imaging and
high probability that visualized lesions would be confirmed as insulinomas were not operated.
One patient with slightly increased uptake of the tracer in the body of the pancreas was finally
not qualified to the surgery and is in the observational group. Six patients with positive results
Fig 3. Blood glucose level versus time after injection of Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-
4—the group of patients with MTC.
doi:10.1371/journal.pone.0160714.g003
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of studied method were unfortunately lost for follow up. However in case of 18 patients, in
whom other non-invasive imaging examinations were negative or inconclusive, it was possible
to localize precisely pancreatic tumors.
Christ andWild and co-workers [21] reported that GLP-1 receptor imaging with [Lys40(Ahx-
DTPA-111In)NH2]-exendin4 detected correctly the insulinoma in 19 out of 20 patients, what
results in 95% sensitivity (95% CI 75–100) and 25% specificity (95% CI 3–71). These values were
also compared with results for structural imaging (CT/MRI): 47% sensitivity (05% CI 27–68)
and 100% specificity (95% CI 45–100). The authors concluded that GLP-1 receptor imaging with
111In labelled exendin-4 is a more sensitive method for the detection of insulinoma than CT/
MRI and have substantial impact on a clinical management of patients with endogenous hyper-
insulinemic hypoglycemia. They also reported incidences of hypoglycemia after the injection of
labelled GLP-1 analogue. Twenty (67%) out of 30 patients with suspicion of benign insulinoma
required an exogenous glucose infusion to equalize the blood glucose level, but no serious epi-
sodes of hypoglycemia were observed. Similar information could be found in their previous
study devoted to patients with malignant insulinoma [18].
A question, important for the safety of the patients in whom scintigrapy with labelled GLP-
1 analogue is performed, has been raised whether the GLP-1 peptide, similarly to a native GLP-
1, may disturb hypoglycemia counterregulation by suppression of glucagon secretion. In the
study published in 2002 [27] it was shown that GLP-1 does not impair overall hypoglycemia
counterregulation except for a reduction in GH responses, which is in line with other findings
demonstrating pituitary actions of GLP-1. The insulinotropic action of GLP-1 was evaluated as
negligible, if plasma glucose concentrations falls below 4.3 mmol/l. The author quoted also
other publications supporting the statement that hypoglycemia in response to exogenous GLP-
1 has only been observed under artificial conditions, i.e. the concomitant administration of
GLP-1 and iv glucose. In fasting subjects or in combination with oral nutrient intake, there is
no potential of GLP-1 to cause hypoglycemia [28–32]. Lerche and co-workers [33] in random-
ized, double-blind placebo-controlled cross-over study in eight healthy men assessed the safety,
in terms of hypoglycemia, of a continuously infused pharmacological dose of native GLP-1
during long-term fasting. They concluded that the counter-regulatory response during 48 h
of subcutaneous GLP-1 infusion was preserved despite long-term fasting with no apparent
increased risk of hypoglycemic episodes. No reactive hypoglycemia was observed when the fast
was followed by an oral glucose tolerance test. Thus use of long-acting GLP-1 analogues may
not increase the risk of hypoglycaemia. However, one should remember that these experiments
were conducted in healthy volunteers with normal reactions preventing hypoglycaemia.
We were trying to verify this finding in a group of patients who were not burdened by hypo-
glycemic episodes related to the natural course of their disease and we did not observe such phe-
nomenon in patients with MTC without previous problems with blood glucose levels (see Fig 3).
Despite our study was dedicated mainly for localization of occult insulinoma we were trying
also to assess the utility of GLP-1 receptor imaging in case of other disorders, which may cause
severe or recurrent hypoglycemia. Therefore we would like to mention that the examination
with radiolabelled GLP-1 could be also helpful for the differentiation of nesidioblastosis and
insulinoma. Moreover, in clinical practice it should be expected that insulinoma may coexist
with nesidioblastosis [25]. 99mTc GLP-1 scintigraphy may be helpful in diagnosis of various
forms of nesidioblastosis (considering different genetic patterns) enabling to determine the
range of surgical treatment in its focal and diffuse type, if suitable. Patients with diagnosed
focal form of nesidioblastosis can be completely cured by a limited pancreatectomy and the
two forms of this syndrome could be distinguished by morphological criteria. Moreover, a spe-
cific genetic background of that difference was confirmed by molecular findings but genetic
tests have not been still generally available [34]. It seems that the GLP-1 receptor imaging
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could be an alternative approach to this issue. However presented above group of patients is of
course too small to draw any conclusions.
Malignant form of insulinoma is rare (up to 15% of all insulinomas), and may frequently
lack GLP-1 receptors [22]. But this statement does not completely preclude usefulness of GLP-1
receptor imaging in the case of malignant insulinoma, as it was shown by Eriksson and co-work-
ers [23]. In our Center the GLP-1 receptor imaging with the use of Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4 was performed in 3 patients with malignant insulinoma. Two other
patients were diagnosed with malignant insulinoma before the examination with labeled GLP-1
analogue. One of those patient was included in the study—the metastatic lesions in the liver
occurred after excision of the pancreatic tumor. The results of the [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4 scans were very interesting: for two patients the scan was negative for
both primary tumor and liver metastases, in the next case the focal accumulation of the tracer
was revealed in the localization of a removed pancreatic head (recurrence of the disease) but
metastases were negative. This phenomenon inidcates the different biology of primary lesions
and metastases, already well known in neuroendocrine neoplasms.
At the end it is worth to emphasize a high tumor to non-tumor (T/nT) ratio for Lys40(Ahx-
DTPA-111In)NH2]-exendin-4, which we observed in our study. For optimizing the acquisition
protocol, amino acids, Gelofusine, fragmented albumin or other substances should be used for
blocking tracer uptake by proximal kidney tubules, because of a very high kidney to non-tumor
ratio. It will probably improve diagnostic efficiency of the GLP-1 scintigraphy, especially when
small pathological lesions are located in proximity to the kidneys or in the pancreatic head and
tail [18,25]. It should be emphasized that only the use of hybrid technology SPECT/CT allows
proper lesions assessment in the scintigraphic scans. The best quality images and the most suit-
able relation of T/nT ratio to K/nT were obtained 5–6 hours after [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4 (740MBq) injection. Additional delayed images could be still needed
in patients with negative early scans. In previous paper [25], on the basis of biokinetics and
dose assessment studies, it was reported that the average effective dose for patients after GLP-1
analogues labelled with 99mTc is comparable with the radiation dose to patients after SRS per-
formed with 99mTc-EDDA/HYNIC-Tyr3-octreotide. Despite some technical difficulties to
overcome (a very high kidneys’ uptake), the new compound seems to be an effective new tracer
for clinical practice and appears to be safe for the patient and the staff.
Due to a very high density of GLP-1 receptors in benign insulinomas, it is possible that
examinations with all GLP-1 tracers (different GLP-1 analogues labelled with 99mTc, 111In,
68Ga, 18F or 64Cu) will be characterized by a similar, very high diagnostic accuracy. As
18F-DOPA PET has been also presented as the preferred compound for insulinoma detection
[35], the comparative studies are needed to prove diagnostic utility of both methods.
Conclusions
In our study 99mTc-GLP1-SPECT/CT proved to be helpful imaging method in the manage-
ment of patients with severe hypoglycemia. 99mTc-GLP1-SPECT/CT could be considered in
the former stages of diagnostic schemes to optimize the procedures and to enable, by proper
localization of the pancreatic lesion, effective, healthy pancreatic tissues sparing, surgical treat-
ment. In case of occult insulinomas this imaging technique may eliminate also the need to per-
form invasive procedures, which also in some cases have limited efficacy.
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